Voie rectale < Voie souscutanée < Voie sublinguale

Facettes :

List of bibliographic references indexed by Voie souscutanée

Number of relevant bibliographic references: 19.

Ident.	Authors (with country if any)	Title
004155 (2003)	Nancy Bélanger [Canada] ; Laurent Grégoire [Canada] ; Abdallah Hadj Tahar [Canada] ; Paul J. Bédard [Canada]	Chronic treatment with small doses of cabergoline prevents dopa‐induced dyskinesias in parkinsonian monkeys
004360 (2002)	Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie]	Paradoxical response to apomorphine in a case of atypical parkinsonism
004571 (2002)	Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]	Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients
004608 (2002)	Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque]	Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up
004661 (2001)	Han-Cheng Wang [Taïwan] ; Yoloung Hsieh [Taïwan]	Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy
004956 (2000)	Frank Birklein [Allemagne] ; Frank Erbguth [Allemagne]	Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A—A preliminary observation
004958 (2000)	Stewart A. Factor [États-Unis] ; Diane L. Brown [États-Unis] ; Eric S. Molho [États-Unis]	Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease
004B41 (2000)	Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]	Apomorphine: An underutilized therapy for Parkinson's disease
005069 (1998)	John D. O'Sullivan [Australie] ; Andrew J. Hughes [Australie]	Apomorphine‐induced penile erections in Parkinson's disease
005107 (1998)	T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas]	The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study
005566 (1996)	F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie]	Transient atrial fibrillation after subcutaneous apomorphine bolus
005991 (1995)	S. Przedborski [Belgique] ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand [Belgique]	Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans
005A37 (1995)	S. T. Gancher [États-Unis] ; J. G. Nutt [États-Unis] ; W. R. Woodward	Apomorphine infusional therapy in Parkinson's disease : clinical utility and lack of tolerance
005E49 (1993)	A. J. Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern	Subcateneous apomorphine in Parkinson's disease: response to chronic administration for up to five years
005E98 (1993)	U. Bonuccelli [Italie] ; P. Piccini [Italie] ; P. Del Dotto [Italie] ; G. Rossi ; G. U. Corsini ; A. Muratorio [Italie]	Apomorphine test for dopaminergic responsiveness: a dose assessment study
006085 (1992)	J.-F. De Saint Victor [France] ; C.-L. Gervason	Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine
006295 (1990)	M. E. Rodriguez [Espagne] ; M. R. Luquin [Espagne] ; G. Lera [Espagne] ; G. Delgado [Espagne] ; J. M. Salazar [Espagne] ; Obeso [Espagne]	Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion
006476 (1989)	J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse]	Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease
006659 (1987)	N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden	Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Voie souscutanée" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Voie souscutanée" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Voie souscutanée
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024